Management of accidental exposure to hepatitis C virus;Gestion des accidents d'exposition au virus de l'hepatite C

Medecine et Maladies Infectieuses

Volumn 30, Issue SUPPL. 1, 2000, Pages 49-52

  Bouvet, E ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Acute hepatitis; ALT; Anti HCV; Antibodies; Blood exposure; HCV; PCR

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS ANTIBODY;

CONFERENCE PAPER; EXPOSURE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEROLOGY; VIRUS TRANSMISSION;

EID: 0034162208     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Circulaire DGS/DH/ DRT/DSS n° 98/228 du 9 avril 1998 relative aux recommandations de mise en œuvre d'un traitement antirétroviral après exposition au risque de transmission du VIH. Principales dispositions. Bull Epidemiol Hebd 1998; 130-1: 30.
2. Circulaire DGS/DH/DRT n° 99/680 du 8 décembre 1999 relative aux recommandations à mettre en œuvre après exposition aux risques de transmission du VHb et du VHC par le sang.
3. Desenclos JC, Dubois F, Couturier E, Pillonel J, Roudot-Thoraval F, Guignard E, et al. Estimation du nombre de sujets infectés par le VHC en France 1994-1995. Bull Epidemiol Hebd 1996; 5: 22.
4. Zuckerman J, Clewley G, Griffiths P, Cockcroft A. Prevalence of hepatits C antibodies in clinical health care workers. Lancet 1994; 343: 1618-20.
5. Petrosillo N, Puro V, Ippolito G, Di Nardo G, Albertoni F, Chiaretti, et al. And al Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in health care workers: A multiple regression analysis of risk factors. J Hosp Infect 1995; 30: 273-81.
6. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. J Infect Dis 1994; 170: 1410-7.
7. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Prevalence of antibodies against hepatitis C virus infection among health care workers in Stockholm. Scand J Gastroenterol 1994: 29: 360-2.
8. Djeriri K, Fontana L, Laurichesse H, Peigue-Lafeuille H, Henquell I, Chamoux A, et al. Seroprevalence of markers of viral hepatitis A, B, and C in hospital personnel at the Clermont-Ferrand University Hospital Center. Presse Med 1996; 25: 145-50.
9. Maillard MF, Poynard T, Dubreuil P, Agostini H, Hautecœur B, Pillot J, Chaput JC. Prevalence of serum anti-hepatitis C virus antibodies and risk factors of contamination in the personnel of a hospital in the Paris region. A prospective survey. Gastroenterol Clin Biol 1996; 20: 1053-7.
10. Domart M, Hamidi K, Antona D, Abiteboul D, Couroucé AM, Bouvet E. Risque professionnel d'hépatite C chez le personnel de santé. Résultats préliminaires d'une enquête multicentrique. Bull Epidemiol Hebd 1995; 45: 198-9.
11. Polish LB, Tong MJ, Co RL, Coleman PJ, Alter MJ. Risk feactors for hepatitis C virus infection among health care personnel in a community hospital. Am J Infect Control 1993; 21: 196-200.
12. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers? Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23: 273-7.
13. Petrosillo N, Puro V, Jagger J, Ippolito G. The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Am J Infect Control 1995; 23: 278-85.
14. Gœtz AM, Ndimbie OK, Wagener MM, Muder RR. Prevalence of hepatitis C Infection in health care workers affiliated with a liver transplant center. Transplantation 1995; 59: 990-4.
15. CDC, Recommandations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. MMWRS 1998; 47: n° RR-19.
16. Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16: 1109-14.
17. Sartori M, La Terra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C via blood splash into conjunctival blood exposure (letter). Scand J Infect Dis 1993; 25: 270-1.
18. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
19. Poynard T, Marcellin P, Lee SS, Nierderau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-32.